FINWIRES · TerminalLIVE
FINWIRES

Oncolys BioPharma Gains Full Japanese Approval for Esophageal Cancer Therapy

By

Oncolys BioPharma (TYO:4588) has received full marketing approval from Japan's Ministry of Health, Labour and Welfare for Telomelysin Injection to treat esophageal cancer patients ineligible for curative resection or chemoradiotherapy.

It is the world's first oncolytic adenovirus product approved for this indication, based on data from a domestic pivotal study, according to a Tokyo bourse filing on Monday.

The therapy selectively replicates in and destroys cancer cells by leveraging telomerase activity, offering a new option for patients with limited alternatives.

Under a 2024 agreement, FUJIFILM Toyama Chemical will handle commercialization in Japan after NHI price listing.

Oncolys will receive a milestone payment from its partner, recorded as revenue for fiscal 2026, with additional product supply payments recognized progressively after launch.

The company plans to launch Telomelysin in Japan later this year and is currently assessing the approval's financial impact.

Related Articles

Asia

Cosmo Chemical Shares Rise 6% on KRW15.5 Billion EcoPro Supply Deal

Cosmo Chemical (KRX:005420) secured a supply contract for cobalt sulfate, a secondary battery cathode material, from EcoPro (KOSDAQ:086520) subsidiary EcoPro EM, according to a Tuesday Korea Exchange filing.The contract, worth 15.47 billion won, is valid till Dec. 31, 2031.Shares of Cosmo Chemical rose nearly 6% in recent trade.

KOSDAQ:086520KRX:005420
Asia

Grasim Industries Earmarks INR31 Billion Capex for Lyocell Capacity Expansion

Grasim Industries (NSE:GRASIM, BOM:500300) has received board approval for Phase II expansion of its Lyocell capacity in Harihar, Karnataka, involving capital expenditure of 30.9 billion Indian rupees, according to a Monday filing with the Indian bourses.The expansion will be executed in two phases, adding a total capacity of 110,000 tonnes per annum (TPA) through two 55,000 TPA lines. The first phase is expected to be completed by mid-2028, followed by the second phase by mid-2030.The Phase II expansion will complement Phase I of its Lyocell plant in Harihar, which is already under construction and is expected to be commissioned by mid-2027, the filing stated.

BOM:500300NSE:GRASIM
Asia

SEC Wins KRW4.2 Billion Equipment Supply Order from Hanwha Aerospace

South Korean tech and inspection company SEC (KOSDAQ:081180) won an order from Hanwha Aerospace (KRX:012450) to supply the latter with non-destructive testing equipment, according to a Tuesday filing with the Korea Exchange.The contract, worth 4.2 billion won, is valid till Dec. 31, 2027.Shares of Hanwha Aerospace rose nearly 1% in recent trade.

KOSDAQ:081180KRX:012450